Company intelligence / Profile preview

Bright Green Corporation

Grants, New Mexico, United Statesbright.green ↗

Ownership: Public · BGXX
Employees: ~5
Development stage: Preclinical

Overview

Bright Green is positioning itself as the first federally-authorized producer of plant-based drugs and APIs in the US. The company is currently in the process of completing construction and obtaining final DEA approval for its facilities.

Therapeutic areas: OtherNeurology
Modalities: Plant-based drugsActive Pharmaceutical Ingredients (APIs)
Industry: Biotech

Partnerships

Asia Capital Pioneers Group (ACPG)Benuvia Pharmaceuticals

Financials

Market cap: $7.3M
Total revenue: $0
Enterprise value: $7.2M

Beyond the preview

Go deeper on Bright Green Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bright Green Corporation.

Explore the full profile